Author

J. D. Phelan

Observed name: James D. Phelan

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Observed institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

OpenAlex ID: A5030912922

Phase 2 Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (teddi‐r) for Secondary Cns Lymphoma

2023 · M. Roschewski, J. Simard, et al. · Hematological Oncology · 4

316 | Multi‐targeted Therapy With Vipor‐p in Relapsed/refractory Diffuse Large B‐cell Lymphoma: Updated Analysis of Efficacy and Minimal Residual Disease

2025 · C. Melani, R. Lakhotia, et al. · Hematological Oncology · 1

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)

2023 · C. J. Melani, R. Lakhotia, et al. · Hematological Oncology · 1

Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes

2026 · James D. Phelan, Julius C. Enssle, et al. · Annual Review of Cancer Biology

Works count: 4

Citation count: 6

H-index: 1

I10-index: